<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77406">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097849</url>
  </required_header>
  <id_info>
    <org_study_id>109MS307</org_study_id>
    <nct_id>NCT02097849</nct_id>
  </id_info>
  <brief_title>Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.</brief_title>
  <official_title>An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria
      toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who
      have been treated with Tecfidera (BG00012) versus those treated with non pegylated
      interferon (IFN).

      Secondary objective is to evaluate the immune response to vaccination with 23-valent
      pneumococcal polysaccharide vaccine (PPSV23) [a mostly T cell-independent humoral response]
      and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) [T
      cell-dependent neoantigen response].
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with a ≥2-fold rise in anti-tetanus serum immunoglobulin G (IgG) levels from pre-vaccination to 4 weeks after Td vaccination.</measure>
    <time_frame>Up to week 4 post vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a ≥4-fold rise in anti-tetanus serum IgG levels from pre-vaccination to 4 weeks after Td vaccination.</measure>
    <time_frame>Up to week 4 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a ≥2-fold and a ≥4-fold rise in anti-pneumococcal serum IgG levels against serotypes 3 and 8 from pre-vaccination to 4 weeks after PPSV23 vaccination.</measure>
    <time_frame>Up to week 4 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a ≥2-fold and a ≥4-fold rise in anti-meningococcal serum IgG levels against serotype C From pre-vaccination to 4 weeks after MCV4 vaccination.</measure>
    <time_frame>Up to week 4 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The geometric mean titer ratios from pre-vaccination to 4 weeks after Td, PPSV23, and MCV4 vaccinations.</measure>
    <time_frame>Up to week 4 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing adverse events (AEs)</measure>
    <time_frame>Day 1 to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing serious adverse events (SAEs).</measure>
    <time_frame>Screening to Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Relapsing Forms of Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Tecfidera Treated Plus Vaccinations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:
Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Pegylated IFN Treated Plus Vaccinations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:
Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimethyl fumarate</intervention_name>
    <description>Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera</description>
    <arm_group_label>Tecfidera Treated Plus Vaccinations</arm_group_label>
    <other_name>DMF</other_name>
    <other_name>BG00012</other_name>
    <other_name>Tecfidera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tetanus diphtheria toxoids vaccine</intervention_name>
    <description>Administered as described in the treatment arm</description>
    <arm_group_label>Non-Pegylated IFN Treated Plus Vaccinations</arm_group_label>
    <arm_group_label>Tecfidera Treated Plus Vaccinations</arm_group_label>
    <other_name>Td</other_name>
    <other_name>Tenivac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent pneumococcal polysaccharide vaccine</intervention_name>
    <description>Administered as described in the treatment arm</description>
    <arm_group_label>Non-Pegylated IFN Treated Plus Vaccinations</arm_group_label>
    <arm_group_label>Tecfidera Treated Plus Vaccinations</arm_group_label>
    <other_name>Pneumovax 23</other_name>
    <other_name>PPSV23</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)</intervention_name>
    <description>Administered as described in the treatment arm</description>
    <arm_group_label>Non-Pegylated IFN Treated Plus Vaccinations</arm_group_label>
    <arm_group_label>Tecfidera Treated Plus Vaccinations</arm_group_label>
    <other_name>MCV4</other_name>
    <other_name>Menveo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-pegylated interferon</intervention_name>
    <description>Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.</description>
    <arm_group_label>Non-Pegylated IFN Treated Plus Vaccinations</arm_group_label>
    <other_name>IFN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have a confirmed diagnosis of RRMS per the 2010 McDonald criteria.

          -  Must have a known tetanus immunization history with most recent tetanus vaccination
             given 2 to 15 years prior to Screening and an anti-tetanus IgG titer at Screening
             that is less than or equal to one-half the upper limit of detection for the assay.

          -  Must have been on a stable approved dose of Tecfidera (240 mg twice daily [BID])
             [Group 1] for ≥6 months or on a stable approved dose of a non-pegylated IFN (e.g.,
             Avonex, Betaseron, Rebif, Extavia) [Group 2] for ≥3 months prior to Day 1.

        Key Exclusion Criteria:

          -  Clinical relapse requiring treatment within 30 days prior to Day 1.

          -  Pneumococcal vaccination within 5 years prior to Screening.

          -  Previous exposure to meningococcal vaccines.

          -  Known hypersensitivity to Td, PPSV23, or MCV4 or their components.

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 23, 2016</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>pneumococcal</keyword>
  <keyword>meningococcal</keyword>
  <keyword>tetanus diphtheria</keyword>
  <keyword>immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Dimethyl Fumarate</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
